Blockade of tumor necrosis factor-α converting enzyme (TACE) enhances IL-1β and IFN-γ via caspase-1 activation: A probable cause for loss of efficacy of TACE inhibitors in humans?

European Journal of Pharmacology

Volumn 701, Issue 1-3, 2013, Pages 106-113

  Sharma, Manoranjan ^a   Mohapatra, Jogeswar ^a   Acharya, Aviseka ^a   Deshpande, Shrikalp S ^b   Chatterjee, Abhijit ^a   Jain, Mukul R ^a  

^a ZYDUS RESEARCH CENTRE   (India)

^b K B INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH   (India)

Author keywords

Caspase 1; Interferon ; Interleukin 1 ; TNF converting enzyme

Indexed keywords

CONCANAVALIN A; CYTOKINE; DPC 333; GAMMA INTERFERON; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; MESSENGER RNA; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; UPREGULATION;

ADAM PROTEINS; ANIMALS; CASPASE 1; CELL MEMBRANE; CONCANAVALIN A; ENZYME ACTIVATION; FEMALE; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-1BETA; LEUKOCYTES, MONONUCLEAR; MACROPHAGES; MICE; MICE, INBRED BALB C; PROTEASE INHIBITORS; QUINOLINES; SPECIES SPECIFICITY; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 84873699789     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2012.12.002     Document Type: Article

References (33)

1. R. Aggarwal, A.M. Manadan, A. Poliyedath, W. Sequeira, and J.A. Block Safety of etanercept in patients at high risk for mycobacterial tuberculosis infections J. Rheumatol. 36 2009 914 917
2. K. Akassoglou, L. Probert, G. Kontogeorgos, and G. Kollias Astrocyte-specific but not neuron-specific transmembrane TNF triggers inflammation and degeneration in the central nervous system of transgenic mice J. Immunol 158 1997 438 445
3. L. Alexopoulou, M. Pasparakis, and G. Kollias A murine transmembrane tumor necrosis factor (TNF) transgene induces arthritis by cooperative p55/p75 TNF receptor signaling Eur. J. Immunol. 27 1997 2588 2592
4. A. Argade, R. Bahekar, J. Desai, P. Thombare, K. Shah, S. Gite, R. Sunder, R. Ranvir, D. Bandyopadhyay, G. Chakrabarti, A. Joharapurkar, J. Mahapatra, A. Chatterjee, H. Patel, M. Shaikh, M. Jain, and P. Patel Design, synthesis and biological evaluation of γ-lactam hydroxamate based TACE inhibitors. Med Chem. Commun. 2 2011 966 972
5. R.A. Black, C.T. Rauch, C.J. Kozlosky, J.J. Peschon, J.L. Slack, M.F. Wolfson, B.J. Castner, K.L. Stocking, P. Reddy, S. Srinivasan, N. Nelson, N. Boiani, K.A. Schooley, M. Gerhart, R. Davis, J.N. Fitzner, R.S. Johnson, R.J. Paxton, C.J. March, and D.P. Cerretti A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells Nature 385 1997 729 733
6. D.C. Blaydon, P. Biancheri, W.L. Di, V. Plagnol, R.M. Cabral, M.A. Brooke, D.A. van Heel, F. Ruschendorf, M. Toynbee, A. Walne, E.A. O'Toole, J.E. Martin, K. Lindley, T. Vulliamy, D.J. Abrams, T.T. MacDonald, J.I. Harper, and D.P. Kelsell Inflammatory skin and bowel disease linked to ADAM17 deletion N. Engl. J. Med. 365 2011 1502 1508
7. T.O. Crişan, T.S. Plantinga, F.L. van de Veerdonk, M.F. Farcaş, M. Stoffels, B.J. Kullberg, J.W. van der Meer, L.A. Joosten, and M.G. Netea Inflammasome-independent modulation of cytokine response by autophagy in human cells PLoS One 6 2011 e18666
8. E.H. Choy, and G.S. Panayi Cytokine pathways and joint inflammation in rheumatoid arthritis N. Engl. J. Med. 344 2001 907 916
9. E. Decoster, B. Vanhaesebroeck, P. Vandenabeele, J. Grooten, and W. Fiers Generation and biological characterization of membrane-bound, uncleavable murine tumor necrosis factor J. Biol. Chem. 270 1995 18473 18478
10. P.E. Dekkers, F.N. Lauw, T. ten Hove, A.A. te Velde, P. Lumley, D. Becherer, S.J. van Deventer, and T. van der Poll The effect of a metalloproteinase inhibitor (GI5402) on tumor necrosis factor-alpha (TNF-alpha) and TNF-alpha receptors during human endotoxemia Blood 94 1999 2252 2258
11. C.A. Dinarello Interleukin-1 beta, interleukin-18, and the interleukin-1 beta converting enzyme Ann. N. Y. Acad. Sci. 856 1998 1 11
12. M.A. Gavrilin, and M.D. Wewers Francisella recognition by inflammasomes: differences between mice and men Front. Microbiol. 2 2011 11
13. M. Grell, E. Douni, H. Wajant, M. Löhden, M. Clauss, B. Maxeiner, S. Georgopoulos, W. Lesslauer, G. Kollias, K. Pfizenmaier, and P. Scheurich The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor Cell 83 1995 793 802
14. M. Grootveld, and M.F. McDermott BMS-561392. Bristol-Myers Squibb Curr. Opin. Investig. Drugs 4 2003 598 602
15. L.A. Joosten, M.M. Helsen, F.A. van de Loo, and W.B. van den Berg Anti-cytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: a comparative study using anti-TNF-α, anti-IL-1α/β, and IL-1Ra Arthritis Rheum. 39 1996 797 809
16. J.M. Kahlenberg, and G.R. Dubyak Differing caspase-1 activation states in monocyte versus macrophage models of IL-1beta processing and release J. Leukoc. Biol. 76 2004 676 684
17. P.A. Kenny Tackling EGFR signaling with TACE antagonists: a rational target for metalloprotease inhibitors in cancer Expert Opin. Ther. Targets 11 2007 1287 1298
18. S. Mariathasan, D.S. Weiss, K. Newton, J. McBride, K. O'Rourke, M. Roose-Girma, W.P. Lee, Y. Weinrauch, D.M. Monack, and V.M. Dixit Cryopyrin activates the inflammasome in response to toxins and ATP Nature 440 2006 228 232
19. P. Matthys, R.J. Lories, B. De Klerck, H. Heremans, F.P. Luyten, and A. Billiau Dependence on interferon-gamma for the spontaneous occurrence of arthritis in DBA/1 mice Arthritis Rheum. 48 2003 2983 2988
20. M.L. Moss, S.L. Jin, M.E. Milla, D.M. Bickett, W. Burkhart, H.L. Carter, W.J. Chen, W.C. Clay, J.R. Didsbury, D. Hassler, C.R. Hoffman, T.A. Kost, M.H. Lambert, M.A. Leesnitzer, P. McCauley, G. McGeehan, J. Mitchell, M. Moyer, G. Pahel, W. Rocque, L.K. Overton, F. Schoenen, T. Seaton, J.L. Su, and J.D. Becherer Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha Nature 385 1997 733 736
21. M.L. Moss, L. Sklair-Tavron, and R. Nudelman Drug insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis Nat. Clin. Pract. Rheumatol. 4 2008 300 309
22. M. Nakahira, H.J. Ahn, W.R. Park, P. Gao, M. Tomura, C.S. Park, T. Hamaoka, T. Ohta, M. Kurimoto, and H. Fujiwara Synergy of IL-12 and IL-18 for IFN-gamma gene expression: IL-12-induced STAT4 contributes to IFN-gamma promoter activation by up-regulating the binding activity of IL-18-induced activator protein 1 J. Immunol. 168 2002 1146 1153
23. R.C. Newton, K.A. Solomon, M.B. Covington, C.P. Decicco, P.J. Haley, S.M. Friedman, and K. Vaddi Biology of TACE inhibition Ann. Rheum. Dis. 60 Suppl 3 2001 iii25 32
24. M.L. Olleros, R. Guler, N. Corazza, D. Vesin, H.P. Eugster, G. Marchal, P. Chavarot, C. Mueller, and I. Garcia Transmembrane TNF induces an efficient cell-mediated immunity and resistance to Mycobacterium bovis bacillus Calmette-Guérin infection in the absence of secreted TNF and lymphotoxin-alpha J. Immunol. 168 2002 3394 3401
25. J.J. Peschon, J.L. Slack, P. Reddy, K.L. Stocking, S.W. Sunnarborg, D.C. Lee, W.E. Russell, B.J. Castner, R.S. Johnson, J.N. Fitzner, R.W. Boyce, N. Nelson, C.J. Kozlosky, M.F. Wolfson, C.T. Rauch, D.P. Cerretti, R.J. Paxton, C.J. March, and R.A. Black An essential role for ectodomain shedding in mammalian development Science 282 1998 1281 1284
26. R.M. Raices, Y. Kannan, A. Sarkar, V. Bellamkonda-Athmaram, and M.D. Wewers A synergistic role for IL-1beta and TNF alpha in monocyte-derived IFN gamma inducing activity Cytokine 44 2008 234 241
27. S.R. Ruuls, R.M. Hoek, V.N. Ngo, T. McNeil, L.A. Lucian, M.J. Janatpour, H. Körner, H. Scheerens, E.M. Hessel, J.G. Cyster, L.M. McEvoy, and J.D. Sedgwick Membrane-bound TNF supports secondary lymphoid organ structure but is subservient to secreted TNF in driving autoimmune inflammation Immunity 15 2001 533 543
28. K.A. Solomon, M.B. Covington, C.P. DeCicco, and R.C. Newton The fate of pro-TNF-alpha following inhibition of metalloprotease-dependent processing to soluble TNF-alpha in human monocytes J. Immunol. 159 1997 4524 4531
29. M.M. Thabet, and T.W. Huizinga Drug evaluation: apratastat, a novel TACE/MMP inhibitor for rheumatoid arthritis Curr. Opin. Investig. Drugs 7 2006 1014 1019
30. J.R. Wands, D.K. Podolsky, and K.J. Isselbacher Mechanism of human lymphocyte stimulation by concanavalin A: role of valence and surface binding sites Proc. Natl. Acad. Sci. 73 1976 2118 2122
31. W. Wannamaker, R. Davies, M. Namchuk, J. Pollard, P. Ford, G. Ku, C. Decker, P. Charifson, P. Weber, U.A. Germann, K. Kuida, and J.C. Randle (S)-1-((S)-2-{[1-(4-amino-3-chloro-phenyl)-methanoyl]-amino}-3, 3-dimethyl-butanoyl)-pyrrolidine-2-carboxylic acid((2R,3S)-2-ethoxy-5-oxo- tetrahydro-furan-3-yl)-amide (VX-765), an orally available selective interleukin (IL)-converting enzyme/caspase-1 inhibitor, exhibits potent anti-inflammatory activities by inhibiting the release of IL-1beta and IL-18. J. Pharmacol. Exp. Ther. 321 2007 509 516
32. L.M. Williams, D.L. Gibbons, A. Gearing, R.N. Maini, M. Feldmann, and F.M. Brennan Paradoxical effects of a synthetic metalloproteinase inhibitor that blocks both p55 and p75 TNF receptor shedding and TNF alpha processing in RA synovial membrane cell cultures J. Clin. Invest. 97 1996 2833 2841
33. Y. Zhang, M. Hegen, J. Xu, J.C. Keith, G. Jin, X. Du, T. Cummons, B.J. Sheppard, L. Sun, Y. Zhu, V.R. Rao, Q. Wang, W. Xu, R. Cowling, C.L. Nickerson-Nutter, J. Gibbons, J. Skotnicki, L.L. Lin, and J. Levin Characterization of (2R,3S)-2-([[4-(2- butynyloxy) phenyl] sulfonyl]amino)-N,3- dihydroxybutanamide, a potent and selective inhibitor of TNF-alpha converting enzyme Int. Immunopharmacol. 4 2004 1845 1857